Ambuj Kumar1,2, Rahul Mhaskar1, Brenda J Grossman3, Richard M Kaufman4, Aaron A R Tobian5, Steven Kleinman6, Terry Gernsheimer7, Alan T Tinmouth8, Benjamin Djulbegovic1,2. 1. Division of Evidence-Based Medicine, Department of Internal Medicine, Morsani College of Medicine, University of South Florida, Tampa, Florida. 2. Moffitt Cancer Center, Tampa, Florida. 3. Washington University School of Medicine, St Louis, Missouri. 4. Brigham and Women's Hospital, Boston, Massachusetts. 5. Johns Hopkins Hospital, Baltimore, Maryland. 6. Center for Blood Research, The University of British Columbia, Vancouver, British Columbia, Canada. 7. University of Washington Medical Center and Seattle Cancer Care Alliance, Seattle, Washington. 8. Ottawa Hospital and Research Institute, Ottawa, Ontario, Canada.
Abstract
BACKGROUND: Platelet (PLT) transfusion is indicated either prophylactically or therapeutically to reduce the risk of bleeding or to control active bleeding. Significant uncertainty exists regarding the appropriate use of PLT transfusion and the optimal threshold for transfusion in various settings. We formulated 12 key questions to assess the role of PLT transfusion. STUDY DESIGN AND METHODS: We performed a systematic review (SR) of randomized controlled trials (RCTs) and observational studies. A comprehensive search of PubMed, Web of Science, and Cochrane registry of controlled trials was performed. Methodologic quality of included studies was assessed and a meta-analysis was performed if more than two studies with similar designs were identified for a specific question. RESULTS: Seventeen RCTs and 55 observational studies were included in the final SR. Results from RCTs showed a beneficial effect of prophylactic compared with therapeutic transfusion for the prevention of significant bleeding in patients with hematologic disorders undergoing chemotherapy or stem cell transplantation. We found no difference in significant bleeding events related to the PLT count threshold for transfusion or the dose of PLTs transfused. Overall methodologic quality of RCTs was moderate. Results from observational studies showed no evidence that PLT transfusion prevented significant bleeding in patients undergoing central venous catheter insertions, lumbar puncture, or other surgical procedures. The methodologic quality of observational studies was very low. CONCLUSION: We provide a comprehensive assessment of evidence on the use of PLT transfusions in a variety of clinical settings. Our report summarizes current knowledge and identifies gaps to be addressed in future research.
BACKGROUND: Platelet (PLT) transfusion is indicated either prophylactically or therapeutically to reduce the risk of bleeding or to control active bleeding. Significant uncertainty exists regarding the appropriate use of PLT transfusion and the optimal threshold for transfusion in various settings. We formulated 12 key questions to assess the role of PLT transfusion. STUDY DESIGN AND METHODS: We performed a systematic review (SR) of randomized controlled trials (RCTs) and observational studies. A comprehensive search of PubMed, Web of Science, and Cochrane registry of controlled trials was performed. Methodologic quality of included studies was assessed and a meta-analysis was performed if more than two studies with similar designs were identified for a specific question. RESULTS: Seventeen RCTs and 55 observational studies were included in the final SR. Results from RCTs showed a beneficial effect of prophylactic compared with therapeutic transfusion for the prevention of significant bleeding in patients with hematologic disorders undergoing chemotherapy or stem cell transplantation. We found no difference in significant bleeding events related to the PLT count threshold for transfusion or the dose of PLTs transfused. Overall methodologic quality of RCTs was moderate. Results from observational studies showed no evidence that PLT transfusion prevented significant bleeding in patients undergoing central venous catheter insertions, lumbar puncture, or other surgical procedures. The methodologic quality of observational studies was very low. CONCLUSION: We provide a comprehensive assessment of evidence on the use of PLT transfusions in a variety of clinical settings. Our report summarizes current knowledge and identifies gaps to be addressed in future research.
Authors: Alexander B Pine; Eun-Ju Lee; Mikkael Sekeres; David P Steensma; Daniel Zelterman; Thomas Prebet; Amy DeZern; Rami Komrokji; Mark Litzow; Selina Luger; Richard Stone; Harry P Erba; Guillermo Garcia-Manero; Alfred I Lee; Nikolai A Podoltsev; Lisa Barbarotta; Stephanie Kasberg; Jeanne E Hendrickson; Steven D Gore; Amer M Zeidan Journal: Transfusion Date: 2016-11-22 Impact factor: 3.157
Authors: Matthew A Warner; David Woodrum; Andrew Hanson; Darrell R Schroeder; Gregory Wilson; Daryl J Kor Journal: Transfusion Date: 2017-01-28 Impact factor: 3.157
Authors: Katherine D Ellingson; Mathew R P Sapiano; Kathryn A Haass; Alexandra A Savinkina; Misha L Baker; Koo-Whang Chung; Richard A Henry; James J Berger; Matthew J Kuehnert; Sridhar V Basavaraju Journal: Transfusion Date: 2017-06 Impact factor: 3.157
Authors: Danielle El Haddad; Cezar Iliescu; Syed Wamique Yusuf; William Nassib William; Tarif H Khair; Juhee Song; Elie N Mouhayar Journal: J Am Coll Cardiol Date: 2015-09-08 Impact factor: 24.094
Authors: Jonathan A Stefely; Michael Gailey; Michael Knudson; Larry J Dumont; Thomas J Raife; Noelle I Samia Journal: Transfusion Date: 2020-06-01 Impact factor: 3.157
Authors: Steven L Spitalnik; Darrell Triulzi; Dana V Devine; Walter H Dzik; Anne F Eder; Terry Gernsheimer; Cassandra D Josephson; Daryl J Kor; Naomi L C Luban; Nareg H Roubinian; Traci Mondoro; Lisbeth A Welniak; Shimian Zou; Simone Glynn Journal: Transfusion Date: 2015-08-10 Impact factor: 3.157